Business
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsentan in FSGS
About this update from Travere Therapeutics, Inc.
[{"type":"text","content":"Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsentan in FSGS 11 total abstracts accepted for presentation highlight Travere’s leadership and commitment in the field of rare kidney disease SAN DIEGO, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including two late-breaking oral presentations, at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 2-5, 2023. Presentations will highlight the long-term efficacy and tolerability data of FILSPARI® (sparsentan) in IgA nephropathy (IgAN) from the PROTECT Study, as well as the potential for use of FILSPARI as a first-line treatment in newly diagnosed IgAN patients and in combination with SGLT2 inhibitors. The Company will also present data on the efficacy and tolerability of sparsentan in focal segmental glomerulosclerosis (FSGS) and pediatric proteinuric glomerular diseases, as well as provide insights into patient quality of life and the impact of proteinuria on kidney survival in rare kidney diseases. “The data we and our collaborators are presenting at ASN are a testament to our collective dedication to enhance our scientific understanding of kidney diseases to improve patients’ lives,” said Jula Inrig, M.D., chief medical officer of Travere Therapeutics. “We look forward to presenting data that further demonstrate the clinical benefit of sparsentan in rare kidney diseases and sharing important advancements that have the potential to shape the future of patient care.” Late-Breaker Oral Presentations Sparsentan vs Irbesartan in Patients with Focal Segmental Glomerulosclerosis (FSGS): Results from the Phase 3 DUPLEX TrialAbstract: FR-OR108Oral Abstract Session: High Impact Clinical TrialsHall A; November 3, 10:30-10:45 a.m. ET Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan vs Irbesartan in Patients with Immunoglobulin A Nephropathy (IgAN)Abstract: FR-OR109Oral Abstract Session: High Impact Clinical TrialsHall A; November 3, 10:45-11:00 a.m. ET Oral Presentation Preliminary Findings from the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients with Selected Proteinuric Glomerular DiseasesAbstract: SA-OR84Oral Abstract Session: Pediatric Nephro...